Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!

List view / Grid view

Barts Cancer Institute

 

Proteomics In-Depth Focus 2015
Proteomics In-Depth Focus 2015
article

Proteomics In-Depth Focus 2015

21 September 2015 | By , ,

In this Proteomics In-Depth Focus: David J. Britton & Pedro R. Cutillas from Barts Cancer Institute ask should LC-MS/MS proteomics guide targeted drug selection for cancer patients? And Manfred Raida from the National University of Singapore explains how mass spectrometry and drug development come together...